-
05:37:29 PM

TAK Stock News

03/20/23 9:00 AM
NYSE : TAK
clinical trial
Phase 2b Clinical Trial Results for TYK2 Inhibitor Presented at American Academy of Dermatology Annual Meeting
Results from the Phase 2 b clinical trial of TAK-279, a novel allosteric TYK2 inhibitor developed by Nimbus Therapeutics and owned by Takeda, in patients with moderate-to-severe plaque psoriasis were presented on Saturday, March 18, 2023 at the 2023 American Academy of Dermatology Annual Meeting in New Orleans. The results were presented as part of the...
RHEA-AI
very positive
03/18/23 7:00 AM
NYSE : TAK
clinical trial
Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis
Takeda today announced positive results from a Phase 2 b clinical trial of TAK-279, a highly selective, oral allosteric tyrosine kinase 2 inhibitor, in patients with moderate-to-severe plaque psoriasis. The study met its primary and secondary endpoints, with a statistically significant greater proportion of TAK-279 patients...
RHEA-AI
positive
03/01/23 8:30 AM
NYSE, Nasdaq : HASI, TAK, MNTS
management
Hannon Armstrong Appoints Former EXIM Chairman Kimberly A. Reed and CEO Jeffrey A. Lipson to Board of Directors
Hannon Armstrong Sustainable Infrastructure Capital, Inc., a leading investor in climate solutions, today announced the appointment of Kimberly A. Reed and Jeffrey A. Lipson to its Board of Directors, effective March 1, 2023. Ms. Reed said,“ Hannon Armstrong Sustainable Infrastructure Capital, Inc.— the very first U.S. public company to focus solely on...
RHEA-AI
very positive
02/18/23 5:30 PM
NYSE : TAK
clinical trial
Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
The Phase 3 GRAPHITE Study Met Its Primary Efficacy Endpoint of Significant and Clinically Meaningful Intestinal aGvHD-Free Survival as Compared to Placebo by Day 180 after Allo-HSCT (p No New Safety Signals Were Seen with Vedolizumab Compared with Placebo in Patients Who Received Allo-HSCT Data Were Presented as A Late-Breaking Abstract at The 2023...
RHEA-AI
neutral
02/03/23 6:48 PM
NYSE : TAK
fda approval
U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
TAKHZYRO is the First and Only Prophylaxis Treatment Approved in the U.S. for Children 2 to 1-4 Approval Supported by Extrapolation of Efficacy Data From the Phase 3 HELP Study With Additional Data From the Phase 3 SPRING Study in Pediatric Patients 2 to 1 HAE is a Rare, Debilitating and Potentially Life-Threatening Condition That Causes Unpredictable and...
RHEA-AI
neutral
02/02/23 1:00 AM
NYSE : TAK
acquisition
Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3
LIVTENCITY™ continues to generate high interest and strong uptake since its launch in the U.S. in December 2021, with 87% of U.S. transplant centers having initiated therapy with at least one patient. Plasma-Derived Therapies Immunology, with 502.4 billion yen in reported revenue, delivered outstanding growth of +18% on a CER basis. Growth was driven by higher...
RHEA-AI
positive
01/23/23 3:00 AM
NYSE, Nasdaq : TAK, HCM
acquisition
Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor
Takeda today announced that it has entered into an exclusive licensing agreement with HUTCHMED Limited and its subsidiary HUTCHMED Limited, for the further development and commercialization of fruquintinib outside of mainland China, Hong Kong and Macau. Working with HUTCHMED will enable us to expand our oncology portfolio,...
RHEA-AI
very positive